<DOC>
	<DOCNO>NCT01632917</DOCNO>
	<brief_summary>The objective trial evaluate safety tolerability ATX-101 injection characterize pharmacokinetic profile two ATX-101 formulation .</brief_summary>
	<brief_title>Open-Label Pharmacokinetic Study Final Formulations ATX-101</brief_title>
	<detailed_description>The objective trial evaluate safety tolerability ATX-101 injection characterize pharmacokinetic profile two ATX-101 formulation expect final formulation . ATX-101 administer submental fat subcutaneous injection use maximum propose dose regimen intend labeling .</detailed_description>
	<criteria>Presence sufficient submental fat 50 subcutaneous injection ATX101 space 1.0cm grid safely administer base investigator 's judgment . Males nonpregnant , nonlactating female age 18 65 year , inclusive , date dosing ATX101 . Females must negative serum human chorionic gonadotropin ( hCG ) test result sample obtain screening period admission research facility , dose study material . Females postmenopausal status must menses least one year young 55 year age must serum FSH level â‰¥ 35 mIU/mL . Females childbearing potential must agree practice adequate contraception , judgment investigator , course trial . Serum hemoglobin test result 11.0 g/dL great negative hepatitis B , hepatitis C , HIV test result within 28 day dose study material . Willing able comply understand visit schedule protocolspecified test procedure . Medically able undergo administration study material determine clinical laboratory evaluation obtain within 28 day dose study material investigator identifies clinically significant abnormality . Signed informed consent obtain studyspecific procedure conduct . History intervention treat submental fat ( e.g . liposuction , surgery , lipolytic agent ) . History trauma associate chin neck area , judgment investigator may affect evaluation safety treatment . Loose skin neck chin area reduction submental fat may , judgment investigator , result cosmetically unacceptable outcome . Prominent platysmal band rest interfere evaluation submental fat . Evidence cause enlargement submental area localize subcutaneous fat . Body mass index ( BMI ) &gt; 40.0 screen visit . Refer Appendix B . Use tobacco nicotinecontaining product within 3 month prior dose . Any blood donation significant blood loss within 56 day dose study material plasma donation within 7 day dose study material . A result coagulation test ( PT , PTT ) obtain within 28 day dose study material indicates presence clinically significant bleed disorder . Any medical condition would interfere assessment safety trial would compromise ability subject undergo study procedure give inform consent . Treatment fish oil , aspirin , nonsteroidal antiinflammatory agent ( NSAIDS ) , except acetaminophen , within 7 day dose , anticipated need agent anticoagulative effect ( e.g . warfarin , heparin ) course trial . Treatment oral anticoagulant ( e.g . warfarin ) within 30 day dose study material . Treatment radio frequency , laser procedure , chemical peel , dermal filler neck chin area within 12 month dose study material , botulinum toxin injection neck chin area within 6 month dose study material . History sensitivity component study material . History drug alcohol abuse , judgment investigator , within two year dose study material . Presence positive urine drug alcohol screen test result obtain sample obtain screening period and/or admission research facility confinement period , dose study material . Previous enrollment trial ATX101 . Treatment investigational device agent within 30 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>